Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. Issue 9 (14th May 2020)

• Record Type: Journal Article
• Authors: Tirosh, Amit; Jin, Dexter X.; De Marco, Luiz; Laitman, Yael; Friedman, Eitan
• Is Part Of: Genes, chromosomes & cancer. Volume 59:Issue 9(2020)
• Page Start: 503
• Page End: 516
• Publication Date: 2020-05-14
• Subjects: activating genetic alterations -- GNAS -- oncogene -- gsp mutations -- tumorigenesis; Cancer -- Genetic aspects -- Periodicals; 616.994042
• DOI: 10.1002/gcc.22854
• Languages: English
• ISSNs: 1045-2257

Abstract

Abstract: Activating point mutations in two codons (R201 and Q227) in the alpha subunit of the stimulatory GTP binding protein ( GNAS ) gene—coined gsp mutations—were originally reported in growth hormone secreting pituitary adenomas. In these tumor types, gsp activating mutations were associated with uncontrolled intracellular cAMP accumulation leading to cellular proliferation and tumor formation. Since the original description of gsp mutations in pituitary and later thyroid neoplasia, many more tumors were genotyped for these specific activating mutations. In this paradigm, GNAS is an oncogene that can be activated by other molecular mechanisms, such as DNA amplification and translocation. Herein, we describe the largest account to date of tumor types that harbor pathogenic GNAS genomic alterations (GAs) including the "classical" gsp activating point mutations, delineate some common features of these tumors, and speculate as to the possible mechanisms whereby GNAS activating GAs are associated with the various stages of tumorigenesis.